

## TRAP230 Polyclonal Antibody

### Description

<b>Product type</b>	Primary Antibody
<b>Code</b>	BT-AP09181
<b>Host</b>	Rabbit
<b>Isotype</b>	IgG
<b>Size</b>	20ul, 50ul, 100ul
<b>Immunogen</b>	The antiserum was produced against synthesized peptide derived from human MED12. AA range:611-660
<b>Mol wt</b>	247334
<b>Species reactivity</b>	Human
<b>Clonality</b>	Polyclonal
<b>Recommended application</b>	IHC-p, WB, ELISA
<b>Concentration</b>	1 mg/ml
<b>Full name</b>	TRAP230 Antibody
<b>Synonyms</b>	MED12; ARC240; CAGH45; HOPA; KIAA0192; TNRC11; TRAP230; Mediator of RNA polymerase II transcription subunit 12; Activator-recruited cofactor 240 kDa component; ARC240; CAG repeat protein 45; Mediator

**This product is for research use only, not for use in human, therapeutic or diagnostic procedure.**

### Background

The initiation of transcription is controlled in part by a large protein assembly known as the preinitiation complex. A component of this preinitiation complex is a 1. MDa protein aggregate called Mediator. This Mediator component binds with a CDK8 subcomplex which contains the protein encoded by the gene, mediator complex subunit 12 (MED12), along with MED13, CDK8 kinase, and cyclin C. The CDK8 subcomplex modulates Mediator-polymerase II interactions and thereby regulates transcription initiation and reinitiation rates. The MED12 protein is essential for activating CDK8 kinase. Defects in this gene cause X-linked Opitz-Kaveggia syndrome, also known as FG syndrome, and Lujan-Fryns syndrome.

### Recommended Dilution


WB: 1: 500 - 2000

ELISA: 1: 5000

IHC: 1: 100 - 1: 300

Not yet tested in other applications.

### Images



Immunohistochemistry analysis of paraffin-embedded human lung carcinoma, using MED12 Antibody. The picture on the right is blocked with the synthesized peptide.

### Storage

-20°C for one year